Once you commit a patient to brensocatib, how do you follow therapeutic progress? Do you use biomarkers? Other monitoring strategies?

Anne E. O’Donnell, MD

The Nehemiah and Naomi Cohen Chair in Pulmonary Disease ResearchProfessor of MedicineInterim Chair, Department of MedicineChief, Division of Pulmonary, Critical Care and Sleep MedicineGeorgetown University Medical Center/Medstar Georgetown ...